C4 Therapeutics
CCCC
113 hedge funds and large institutions have $232M invested in C4 Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 29 closing their positions.
452% more call options, than puts
Call options by funds: $2.35M | Put options by funds: $425K
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
1.33% less ownership
Funds ownership: 92.56% → 91.23% (-1.3%)
4% less funds holding
Funds holding: 118 → 113 (-5)
14% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 29
37% less capital invested
Capital invested by funds: $366M → $232M (-$134M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$15M |
| 2 |
Morgan Stanley
New York
|
+$7.52M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.12M |
| 4 |
BlackRock
New York
|
+$3.32M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$19.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.88M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.78M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.76M |
CCCC Hedge Fund Activity: Q4 2024 in Review
113 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2024, worth a combined $232M — down 37% from $366M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CCCC and 25 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 38 added.
The largest buyer was Samlyn Capital, opening a new position worth an estimated $15M. The largest seller was Commodore Capital, exiting entirely with an estimated $19.4M sold.
- 113 institutional investors held C4 Therapeutics (CCCC) as of Q4 2024, down from 118 in Q3 2024.
- Funds reported $232M of C4 Therapeutics stock for Q4 2024, down 37% quarter-over-quarter.
- 25 funds opened new C4 Therapeutics positions in Q4 2024 and 29 closed out, a net change of -4 holders.
- The largest C4 Therapeutics buyer in Q4 2024 was Samlyn Capital, an estimated $15M added.
- The largest C4 Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $19.4M sold.
Based on aggregated 13F filings for Q4 2024.